Evidence map›Paper›PMID 38396974›Full record

ArticleInternational journal of molecular sciences2024

Generation of Endotoxin-Specific Monoclonal Antibodies by Phage and Yeast Display for Capturing Endotoxin.

Alexandra C Fux, Cristiane Casonato Melo, Laura Schlahsa, Nico B Burzan, André Felsberger, Isabel Gessner, Jonathan A Fauerbach, Jutta Horejs-Hoeck, Miriam Droste, Christiane Siewert

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Alexandra C FuxDepartment of Biosciences and Medical Biology, Paris Lodron University of Salzburg, 5020 Salzburg, Austria.ORCID 0000-0001-8745-829X
Cristiane Casonato MeloDepartment of Biosciences and Medical Biology, Paris Lodron University of Salzburg, 5020 Salzburg, Austria.ORCID 0000-0003-1013-585X
Laura SchlahsaResearch and Development Department, Miltenyi Biotec B.V. & Co. KG, 51429 Bergisch Gladbach, Germany.
Nico B BurzanResearch and Development Department, Miltenyi Biotec B.V. & Co. KG, 51429 Bergisch Gladbach, Germany.ORCID 0009-0007-0672-480X
André FelsbergerResearch and Development Department, Miltenyi Biotec B.V. & Co. KG, 51429 Bergisch Gladbach, Germany.
Isabel GessnerResearch and Development Department, Miltenyi Biotec B.V. & Co. KG, 51429 Bergisch Gladbach, Germany.ORCID 0000-0001-9674-161X
Jonathan A FauerbachResearch and Development Department, Miltenyi Biotec B.V. & Co. KG, 51429 Bergisch Gladbach, Germany.ORCID 0000-0002-1540-0352
Jutta Horejs-HoeckDepartment of Biosciences and Medical Biology, Paris Lodron University of Salzburg, 5020 Salzburg, Austria.
Miriam DrosteResearch and Development Department, Miltenyi Biotec B.V. & Co. KG, 51429 Bergisch Gladbach, Germany.ORCID 0009-0001-2438-3291
Christiane SiewertResearch and Development Department, Miltenyi Biotec B.V. & Co. KG, 51429 Bergisch Gladbach, Germany.

Funding

European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie H2020-MSCA-ITN-2018-812661
6 · The paper itself

Abstract

Endotoxin, a synonym for lipopolysaccharide (LPS), is anchored in the outer membranes of Gram-negative bacteria. Even minute amounts of LPS entering the circulatory system can have a lethal immunoactivating effect. Since LPS is omnipresent in the environment, it poses a great risk of contaminating any surface or solution, including research products and pharmaceuticals. Therefore, monitoring LPS contamination and taking preventive or decontamination measures to ensure human safety is of the utmost importance. Nevertheless, molecules used for endotoxin detection or inhibition often suffer from interferences, low specificity, and low affinity. For this reason, the selection of new binders that are biocompatible, easy to produce, and that can be used for biopharmaceutical applications, such as endotoxin removal, is of high interest. Powerful techniques for selecting LPS-binding molecules in vitro are display technologies. In this study, we established and compared the selection and production of LPS-specific, monoclonal, human single-chain variable fragments (scFvs) through two display methods: yeast and phage display. After selection, scFvs were fused to a human constant fragment crystallizable (Fc). To evaluate the applicability of the constructs, they were conjugated to polystyrene microbeads. Here, we focused on comparing the functionalized beads and their LPS removal capacity to a polyclonal anti-lipid A bead. Summarized, five different scFvs were selected through phage and yeast display, with binding properties comparable to a commercial polyclonal antibody. Two of the conjugated scFv-Fcs outperformed the polyclonal antibody in terms of the removal of LPS in aqueous solution, resulting in 265 times less residual LPS in solution, demonstrating the potential of display methods to generate LPS-specific binding molecules.

Indexed as

BacteriophagesSingle-Chain AntibodiesAntibodies, MonoclonalEndotoxinsHumansLipopolysaccharidesPeptide LibrarySaccharomyces cerevisiaeAntibodies, MonoclonalEndotoxinsLipopolysaccharidesPeptide LibrarySingle-Chain Antibodiesantibodiescell sortingendotoxinflow cytometryLALLPS removalmicrobeadsphage displayscFv-Fcyeast display

Identifiers

PMID38396974
PMCPMC10889169

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.